Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA)

Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA)

Introduction: Lymphatic anomalies (LAs) refer to a group of diseases involving systemic dysplasia of lymphatic vessels. These lesions are classified as cystic lymphatic malformation (macrocystic, microcystic or mixed), generalized lymphatic anomaly, and Gorham–Stout disease. LAs occur mainly in chil...

Full description

Bibliographic Details
Main Authors: Michio Ozeki, Ryuta Asada, Akiko M. Saito, Hiroya Hashimoto, Takumi Fujimura, Tatsuo Kuroda, Shigeru Ueno, Shoji Watanabe, Shunsuke Nosaka, Mikiko Miyasaka, Akihiro Umezawa, Kentaro Matsuoka, Takanobu Maekawa, Yohei Yamada, Akihiro Fujino, Satoshi Hirakawa, Taizo Furukawa, Tatsuro Tajiri, Yoshiaki Kinoshita, Ryota Souzaki, Toshiyuki Fukao
Format: Article
Language:English
Published: Elsevier 2019-06-01
Series:Regenerative Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2352320418300518

Internet

http://www.sciencedirect.com/science/article/pii/S2352320418300518

Similar Items